Claret Targets TAVR Stroke Risk With Sentinel Embolic Filter Device

The company launched the SENTINEL trial in the U.S., the first prospective, randomized, controlled, blinded trial in the U.S. of a cerebral protection device for transcatheter aortic valve replacement.